Contents
On this page
- Biotechnology-specific and generic elements of proposal structure
- The page budget as the basis of structure
- The Specific Aims page and the number of aims
- Thrusts and tasks as units of work
- Resolution of a broad ambition into one primary objective
- Feasibility as the most frequently underdeveloped section
- Application of protocol standards to biotechnology proposals
- Short-form proposals and the effects of compression
- Reviewer reading of proposal structure
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · biotechnology proposal structure
Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans
There is no peer-reviewed literature on the structure of biotechnology proposals specifically. There is, however, a well-evidenced body of work on proposal structure in general — page budgets, aims pages, thrust-and-task plans and objective hierarchies — and this article draws on it. The biotechnology-specific elements reflect professional practice and funder convention, and the article distinguishes these from evidence-based recommendations.
Biotechnology proposals fail on structural grounds more often than on scientific grounds. The science is usually defensible; failure more often results from a plan that cannot be read within the page limit, overlapping aims, a work plan without a visible unit of work, and a timeline that does not reconcile with the award term. These problems have established solutions in the general proposal literature, and the solutions transfer almost unchanged to a biotechnology application. What does not transfer is domain judgement about scale-up, strain or cell-line provenance and regulatory timelines, and this element reflects professional practice rather than evidence.
Learning objectives
- Laying out a technical volume against a page budget before drafting the scientific content
- Writing a Specific Aims page that reviewers can score, and determining the number of aims
- Decomposing a research plan into thrusts and tasks so that the work has a visible unit
- Resolving a broad biotechnology ambition into one primary objective and a bounded set of secondary objectives
- Distinguishing generic structural elements of proposals from those that are genuinely specific to biotechnology
- The changes that a short-form proposal makes to structure, and the elements it leaves unchanged
Common misconceptions
- “There is a biotechnology proposal format I should be following.” No such format is established in the peer-reviewed literature. There are funder-specific page budgets and section orders, and there is general proposal practice. A template marketed as biotechnology-specific is a generic template with altered terminology.
- “More aims show more ambition.” NIAID advises drafting two to four Specific Aims, with three the most common choice. Beyond that number the aims begin to overlap, each receives insufficient space, and reviewers interpret breadth as a failure to prioritise.
- “Structure is something I impose at the end, once the science is written.” The page budget constitutes the structure. An NSF-style technical volume that should not exceed 15 pages excluding references, with an introduction of no more than one page, determines how much scientific content each section can accommodate, and this decision must be made before drafting rather than after.
- “A shorter form means a lighter application.” A 1,200-word short-form proposal took applicants an average of 7 days to prepare, compared with 34 days for a conventional proposal. The saving is substantial, but compression requires every structural decision to be made with greater, not lesser, precision.
- “If it is a lab proposal I do not need protocol-level detail.” Any part of the work involving human participants or samples inherits the protocol reporting standard: SPIRIT 2025 provides a 34-item checklist for reporting randomised trial protocols. Reviewers who sit on clinical panels will look for these items whether or not the funder requires them.
Biotechnology-specific and generic elements of proposal structure
The limits of the evidence should be acknowledged at the outset, because they affect how the remainder of this page should be read. The empirical literature on research proposals — what reviewers reward, how long preparation takes, what structural weaknesses recur, how objectives should be bounded — is drawn almost entirely from biomedical, clinical and general science funding 22,28,30. It is sound evidence and it generalises well, because the structural problems are the same regardless of the scientific field: a reviewer with limited time must locate the question, the plan and the feasibility argument within a fixed number of pages.
To our knowledge, no peer-reviewed body of work exists on the biotechnology proposal as a distinct genre. There are no studies of what biotechnology reviewers weight, no evidence on how bioprocess feasibility arguments perform, and no quantitative data on intellectual-property sections. The biotechnology-specific advice on this page — where to place strain provenance, how much scale-up detail a reviewer needs, when to declare regulatory pathway assumptions — is therefore professional practice distilled from funder guidance and reviewer practice, and should be treated as a reasonable default rather than a finding.
The practical consequence is that applicants should not seek a biotechnology template, but should consult the funder’s own page budget and section order and apply general proposal structure within it. Our page on the essential ingredients of a scientific research proposal sets out the content that structure has to carry, and biotechnology subject support is where the domain judgement comes in.
The page budget as the basis of structure
Before drafting, the funder’s limits should be recorded and allocated. For an NSF-style technical volume the convention is a document not exceeding 15 pages excluding references, with the introduction held to no more than one page 18. For an NIH R01 the Specific Aims page is limited to one page and the Research Strategy cannot exceed 12 pages 20. These limits are not minor formatting matters; they are the principal constraint on how much science can be presented, and they determine the shape of the document entirely.
Allocation should proceed in the following order. The aims or introduction should be fixed at its hard limit first, because it is the page every reviewer reads and the one that cannot be allowed to overrun. Space should then be reserved for the feasibility argument — preliminary data, prior work, access to materials and platforms — because a biotechnology plan with no demonstrated capability is the most common structural failure in the genre. The remaining space is available for the research plan, and it is usually less than anticipated. If the remainder cannot accommodate the plan, the plan is too large and a thrust should be removed, rather than the font reduced.
The allocation should be recorded and kept visible while drafting. Its value lies in the discipline it enforces: when a section runs long, the author must decide which other section it is displacing, rather than discovering the overrun at submission, when the only available remedy is deletion of the feasibility argument that was most needed.
Page budgets that determine proposal structure
| Element | Limit or convention | Decision it requires |
|---|---|---|
| NSF-style technical volume | No more than 15 pages, excluding references | How much of the plan can be accommodated before any of it is drafted |
| Introduction, NSF-style volume | No more than 1 page | The problem, the gap and the claim, with no room for background narrative |
| NIH R01 Specific Aims | 1 page | Which aims are retained, and in what order a reviewer encounters them |
| NIH R01 Research Strategy | No more than 12 pages | Significance, innovation and approach in one shared budget |
| Number of Specific Aims | 2 to 4, with 3 most common (NIAID guidance) | What will not be proposed |
| Research plan shape | 2 to 3 thrusts, each with 2 to 3 tasks | The unit of work that is costed, scheduled and delivered |
| Project term | 3 to 5 years | Whether the thrusts can run in parallel or must be sequenced |
| Objective hierarchy | 1 primary objective, up to about 5 secondary | What success means, and what the analysis is sized for |
NSF-style volume conventions and the thrust-and-task plan structure; NIH R01 page limits; NIAID guidance on the number of Specific Aims; and the general proposal literature on objective hierarchies. No biotechnology-specific page conventions are established in the peer-reviewed literature, and the funder’s own call document, which always overrides a convention, should be consulted.
The Specific Aims page and the number of aims
The one-page Specific Aims section is the most constrained piece of writing in research. It must establish the problem, state what is not known, name the central hypothesis or objective, list the aims with their approach and expected outcome, and state what changes if the work succeeds 31,36. NIAID’s guidance is to draft two to four Specific Aims, with three the most common number, and that range should be treated as an upper bound rather than a target.
Three structural rules make an aims page scorable. First, aims must be independent: if Aim 2 cannot be attempted unless Aim 1 returns a particular result, the aims constitute a sequence, and a reviewer will read them as a single aim with risk concentrated at the outset 24,31. The contingency should be stated explicitly with a fallback, or the aims restructured. Second, each aim requires an outcome, not merely an activity — “characterise expression across conditions” is an activity; “determine whether expression is condition-dependent, and if so over what range” is an outcome whose achievement a reviewer can assess 19. Third, the aims must be identical to those that appear in the plan, the timeline and the budget, with the same numbering and the same wording. Inconsistency between these four places is common, and it is read as carelessness.
In a biotechnology proposal, the aim that most often requires rewriting is the engineering aim. “Optimise the construct” or “improve yield” has no endpoint. The aim should specify the dimension being improved, the baseline against which improvement is measured, and the threshold of sufficiency — and where no baseline can be stated, this should be acknowledged and made part of the aim.
The three constraints that shape an aims page. R01 page limits for Specific Aims and Research Strategy, and NIAID guidance on the number of Specific Aims to draft.
A biotechnology Specific Aim, rewritten
An activity with no endpoint
Aim 2: Optimise the engineered strain to improve product yield. We will screen promoter and ribosome binding site variants and characterise the resulting strains using our established analytical pipeline. Successful optimisation will enable scale-up in Aim 3.
“Optimise” and “improve” have no endpoint. There is no baseline, no target and no dimension, so neither the applicant nor the reviewer can determine whether the aim was achieved.
No comparator. Improvement is a relation, and nothing is named to improve on — not the parental strain, not a published figure, not the current process.
“Our established analytical pipeline” asserts a capability without providing evidence for it. Reviewers regard insufficient preliminary data as a core weakness, and an unvalidated readout undermines every number the aim would produce.
Aim 3 is made dependent on Aim 2 succeeding. This converts three aims into one aim with the risk concentrated at the outset, which is the most common structural fault in a multi-aim plan.
No failure branch. If variation proves not to be limiting, the proposal offers no account of what follows, and the reviewer must raise the objection.
An outcome a reviewer can score
Aim 2: Determine whether promoter and ribosome binding site variation is sufficient to raise titre above the baseline we report in Preliminary Data, and identify the limiting step if it is not. We will construct a defined library across both elements, measure titre and specific productivity in fed-batch conditions against the parental strain, and apply our validated LC-MS assay, whose inter-day coefficient of variation is reported in Preliminary Data Figure [n]. Outcome: either a variant exceeding the baseline, with the responsible element identified, or evidence that expression is not limiting, which redirects Aim 3 toward the precursor supply route described in Risks and Alternatives. Aim 2 does not require Aim 1 to succeed.
The dimension, the baseline and the direction are all stated, so success and failure are both describable.
A comparator is named, which converts a vague improvement claim into a measurable contrast.
The assay is evidenced with a reproducibility figure drawn from the applicant’s own preliminary data, so the readout is no longer an assertion.
Independence from Aim 1 is stated explicitly, and the contingency with Aim 3 is declared rather than hidden.
The negative result is given a use, which distinguishes a designed experiment from a speculative one.
A reviewer scoring an aims page asks one question of each aim: whether it will be possible to determine, at the end of the award, that the aim was achieved. The second version answers this in its first sentence; the first version does not answer it at all.
Thrusts and tasks as units of work
The convention recommended for an engineering-style or platform biotechnology proposal is a research plan built as two to three thrusts, each comprising two to three tasks, over a project term of three to five years. The value of this structure lies not in tidiness but in the creation of a unit of work small enough to be costed, scheduled, assigned to a named person and either delivered or not — which is what a reviewer needs in order to find a timeline credible.
A thrust is a coherent line of investigation; a task is a bounded piece of work with an input, a method and a deliverable. A task is well formed if it is possible to state who performs it, approximately how long it takes, what it produces, and what happens if it fails. A task without a stated consequence of failure is an aspiration rather than a task. Two to three tasks per thrust also provides a useful check on scope: a thrust with seven tasks is two thrusts, and a thrust with one task is a task.
The structure should be mapped explicitly. Each aim corresponds to one thrust; each thrust’s tasks appear in the timeline with the same identifiers; and each task’s personnel and consumables appear in the budget justification under the same label 4. Reviewers reconcile these three documents against one another more often than applicants expect, and a mismatch between the plan and the budget is taken as evidence that the plan is not realistic 27,35. Our experimental design notes cover how to specify a task’s methods at the level a reviewer needs.
Resolution of a broad ambition into one primary objective
Biotechnology proposals frequently begin with an ambition rather than a question: a platform to build, a process to improve, a modality to demonstrate. The structural task is to convert that ambition into one primary research question or objective, with no more than about five secondary objectives 19. A single primary objective does not limit the science; it allows the proposal to define success, and it is the objective for which the eventual statistical or analytical plan is powered or sized.
Two instruments are useful. The FINER criteria — five tests of whether a question is feasible, interesting, novel, ethical and relevant — should be applied before substantial investment in writing, and they identify the biotechnology failure mode of a question that is technically interesting but has no stakeholder who needs the answer 2. Where the work has a comparative or clinical arm, the four PICO elements give the question a structure a reviewer can follow: population or system, intervention or manipulation, comparator, outcome. In a bench proposal the comparator is often absent, and naming it — wild type, current best process, published benchmark — usually improves the proposal more than any other single revision. Our page on the PICO framework sets out how the four elements work and where they break down.
Write the primary objective, then write each secondary objective as a sentence that could be answered independently. If a secondary objective cannot be answered without the primary one succeeding, it is a contingency, and it belongs in the risk section rather than the objective list.
Feasibility as the most frequently underdeveloped section
In the general literature on proposal weaknesses, an underdeveloped scientific foundation and insufficient preliminary data recur as reviewer complaints 27,35. In biotechnology the same complaint takes a particular form: the proposal describes a capability that it has not demonstrated. Access to a platform is asserted rather than evidenced; a cell line or strain appears without provenance; a scale-up step is assumed to behave as the bench step did.
The feasibility argument should be structured as a set of claims with supporting evidence, not as a narrative of past work. Each claim should be verifiable: the material can be produced, with the yield achieved; the endpoint can be measured, with the assay and its reproducibility; the instrument or facility is accessible, with the arrangement described; and the organism or line is as stated, with the authentication record 12. Where no data exist, this should be stated plainly together with the mitigation, because reviewers are considerably more tolerant of a declared gap accompanied by a plan than of a gap they discover themselves.
This is the section where a biotechnology proposal differs most from a clinical one, and also where the least evidence exists about what reviewers actually reward. Our reading of funder guidance is that demonstrated measurement capability carries more weight than demonstrated production capability, because a reviewer can imagine solving a yield problem and cannot imagine trusting an unvalidated readout. We offer that as a working judgement, not a finding.
Application of protocol standards to biotechnology proposals
Where any part of the work involves human participants, human samples or identifiable data, the proposal inherits a reporting standard for which it may not have allocated pages. The current protocol standard, SPIRIT 2025, specifies 34 items for randomised trial protocols (its 2013 predecessor’s 33 items were developed from a 59-item preliminary list with 115 stakeholders), covering outcome definitions, allocation, blinding, data management, analysis plans, monitoring and dissemination 29. Many biotechnology proposals with a translational arm include none of this and are reviewed by panels that expect it.
It is not necessary to reproduce all 34 items in a page-limited technical volume. It is necessary to demonstrate awareness of them and to show that they have been decided, which usually requires a compact paragraph naming the outcome definitions, the analysis plan, the data-management arrangement and the governance route, with the full protocol referenced as a separate document 29. Where samples or data are involved, the consent and data-protection structure needs the same treatment — our page on writing a proposal for human protection under EU law covers what belongs in the proposal and what belongs in the protocol, and the SPIRIT checklist lists the items themselves.
The structural point is simple: decide early whether your proposal has a human arm, because if it does, the page budget has to accommodate a governance paragraph and the reviewer pool changes.
Short-form proposals and the effects of compression
Some funders now operate short-form schemes, and their structural implications should be understood in advance 26. In one evaluated scheme a 1,200-word proposal took applicants an average of 7 days to prepare, compared with 34 days for a conventional application — a genuine reduction in burden, and the strongest practical argument for these formats 26.
The effect of compression on structure is less often discussed. At 1,200 words there is no space for a feasibility narrative, so feasibility must be conveyed by the team description and by the precision of the plan. There is no space for more than one or two aims, so the choice of what not to propose becomes the principal intellectual decision. Nor can an unresolved question be concealed: in a 15-page volume a vague primary objective can be obscured by detail, whereas in a short form it constitutes the whole document 18.
The implication for drafting is counterintuitive but reliable. Write the short form first even when you are submitting the long one. If you cannot state the question, the plan and the reason it matters in 1,200 words, the 15 pages will not rescue it — they will only delay the point at which a reviewer notices.
Reviewer reading of proposal structure
Reviewers do not read a proposal linearly, and its structure should reflect the order in which they actually read: the aims or objectives page, then the budget, then the timeline, and then the plan, to check whether the aims are achievable with that funding in that time. The remainder is read in support of a judgement largely formed from those first three documents.
Three structural practices follow. Elements should be numbered, and the numbers kept stable across the plan, the timeline, the budget justification and the aims, so that a reviewer checking consistency finds it immediately. The decision-relevant sentence should be placed first in every section, so that a reviewer seeking the plan need not read a paragraph of context to find it. Risks should be made visible rather than obscured: a named risk with a named mitigation conveys competence, whereas a risk the reviewer identifies independently suggests either ignorance or concealment.
For applicants preparing a first application, our guide to grant proposal writing for medical research covers the submission cycle in more detail, and the page on what makes grant writing hard discusses the time cost candidly. For the writing itself, proposal development support and grant writing support are where we work on structure with applicants.
Key points
Key points
No established biotechnology proposal format exists in the peer-reviewed literature, so the proposal should be built on general proposal structure within the funder’s own page budget. The limits should be fixed first — an NSF-style technical volume of no more than 15 pages excluding references with a one-page introduction, or an R01 with one page of Specific Aims and no more than 12 pages of Research Strategy. The proposal should carry two to four aims, with three the usual choice, each framed as an outcome rather than an activity and each independent of the others. The plan should be built as two to three thrusts of two to three tasks over a three to five year term, so that every element of the work can be costed, scheduled and assessed. The ambition should be resolved into one primary objective and at most approximately five secondary objectives, filtered through the FINER criteria and structured with PICO where a comparison is involved. Feasibility should be supported with evidence rather than assertion, and where any part of the work involves human participants or samples, pages should be allocated to the governance items specified by a protocol standard.
Application to your study
Application to your study
- The page budget should be set before the scientific content is written. The funder’s limits should be placed at the top of the draft and pages allocated to the aims, feasibility and plan. When a section exceeds its allocation, the section from which pages are being taken should be identified.
- The number of aims should be reduced to three. Where there are five, two of them are tasks within another aim or the basis of a second proposal. The advised range is two to four, with three the most common.
- Every aim should be rewritten as an outcome. Verbs such as “characterise”, “optimise” and “investigate” should be replaced with a statement of what can be concluded at the end of the work that cannot be concluded now.
- The plan should be decomposed into tasks and each task tested. Each task should have a named person, a duration, a deliverable and a consequence of failure. A task without a failure consequence is not a task.
- Four documents should be reconciled. The aims, plan, timeline and budget justification should use the same numbering and the same terms for the same work. This should be checked last, deliberately, as a separate pass.
- Assertions of feasibility should be converted into evidenced claims. Every statement of the form “we have established” requires a figure, an authentication record or a named arrangement in support, or an explicit statement that the capability is to be developed, together with the plan for developing it.
- A 1,200-word version should be drafted even when the full-length proposal is to be submitted. It requires a fraction of the time and immediately exposes a vague primary objective.
Frequently asked questions
No such format is established in the peer-reviewed literature. What exists is funder-specific structure — the page budget and section order in the call document — and a general body of evidence on proposal practice that transfers across disciplines. In practice, this means an NSF-style technical volume of no more than 15 pages excluding references with an introduction held to one page, or an NIH R01 with one page of Specific Aims and no more than 12 pages of Research Strategy, and within that a plan built as two to three thrusts of two to three tasks. A template described as biotechnology-specific is a generic structure with biotechnology terminology. Such a template is not without value, but its nature should be understood.
NIAID advises drafting two to four, and three is the most common choice. Three is effective because it gives each aim roughly a third of the Research Strategy, which is sufficient space for an approach, a risk and an alternative. Four is defensible when the aims are genuinely independent and the methods overlap substantially, so that the methodological description can be shared. Two can be strong for a focused mechanistic question. Five or more almost always indicates either that some aims are tasks within another aim, or that the material constitutes two proposals, of which the stronger should be submitted. The number matters less than independence: aims that each require the previous one to succeed constitute one aim with concentrated risk, however they are numbered.
A thrust is a coherent line of investigation, usually corresponding to one aim; a task is a bounded piece of work within it, with an input, a method and a deliverable. The convention is two to three thrusts, each with two to three tasks, across a three to five year term. The reason for adopting it is not neatness but the ability to cost the work: a task is the smallest unit a reviewer can check against the budget and timeline and judge credible or not. A task is well formed if it is possible to name who performs it, approximately how long it takes, what it produces, and what happens if it fails. A task without a stated consequence of failure is an aspiration rather than a task.
Sufficient to resolve the feasibility concern a reviewer would otherwise raise. Insufficient preliminary data and an underdeveloped scientific foundation recur as reviewer-identified weaknesses in the general proposal literature, and in biotechnology the specific form is a capability claimed but not demonstrated. There is no evidence-based threshold, so the following is a working judgement rather than a finding: priority should be given to demonstrating that the endpoint can be measured reliably over demonstrating that the material can be produced at scale, because a reviewer can envisage a yield problem being solved but cannot trust numbers from an unvalidated assay. Where no data exist for a step, the gap should be stated and the mitigation given. A declared gap with a plan is generally acceptable; a gap the reviewer discovers is not.
Only if some arm involves human participants, human samples or identifiable data — in which case, more than most applicants expect. The current protocol standard, SPIRIT 2025, specifies 34 items for randomised trial protocols (its 2013 predecessor’s 33 items were developed from a 59-item preliminary list with 115 stakeholders), covering outcome definitions, allocation, data management, analysis plans and dissemination. It is not necessary to reproduce all 34 in a page-limited technical volume, but a compact paragraph is needed showing that the outcome definitions, the analysis plan, the data-management arrangement and the governance route have been decided, with the full protocol referenced separately. This should be decided early, because a human arm changes both the page budget and the composition of the review panel.
Typically longer than planned. The general evidence on conventional proposals places preparation in the range of weeks of full-time work rather than days: one evaluated short-form scheme recorded an average of 7 days for a 1,200-word application compared with 34 days for a conventional one. These figures come from biomedical and general science funders rather than biotechnology specifically, but there is no apparent reason for the drafting burden to be lower for a proposal with a bioprocess or platform component. The practical implication for planning is that the writing is not the longest part; deciding the aims, generating the missing feasibility data and reconciling the budget with the plan are, and all three must be completed before the final draft.
One. The general guidance is a single primary research question or objective with no more than about five secondary objectives, and it applies to bench and platform work as much as to clinical studies. The reason is that the primary objective defines success, determines the basis of the analysis or sizing, and is the criterion against which the reviewer scores. Proposals with three co-primary objectives usually reflect an undecided priority, and reviewers notice because nothing in the plan is prioritised. The question should be assessed against the five FINER criteria — feasible, interesting, novel, ethical, relevant — before commitment, and where a comparison is involved, the four PICO elements should be used to ensure that the comparator is explicitly named.
Four faults recur. Aims that are sequenced rather than independent, which concentrates all the risk at the outset. Inconsistency between the aims, the plan, the timeline and the budget justification, so that a reviewer checking consistency finds four slightly different projects. A plan too large for the remaining page budget, which is usually resolved by deleting the feasibility argument the plan most needed. Risks left for the reviewer to identify, which suggests either ignorance or concealment, whereas a named risk with a named mitigation conveys competence. None of these is a scientific problem, which is why they warrant a dedicated structural review before submission.
References
- Muhlenberg M, Wassmer T. Writing Research and Grant Proposals. Field Ecology (Springer, Cham). 2025:515-517. doi:10.1007/978-3-031-87547-2_16 read 9 October 2026. doi.org/10.1007/978-3-031-87547-2_16
- Willis LD. Formulating the Research Question and Framing the Hypothesis. Respiratory Care. 2024;69(4). doi:10.4187/respcare.10975 read 9 October 2026. doi.org/10.4187/respcare.10975
- Munch LN, Schuttler KF, Ackermann J, et al. Writing a research funding proposal. Arthroskopie. 2024;37(4):250-253. doi:10.1007/s00142-024-00690-x read 9 October 2026. doi.org/10.1007/s00142-024-00690-x
- Patil SG. Budgeting the Project: Detailing the Required Funding and Expenditure. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:77-91. doi:10.1007/978-981-19-7018-4_7 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_7
- Rajappa M. Checklist for Grant Proposal: Mandatory Elements. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:161-165. doi:10.1007/978-981-19-7018-4_14 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_14
- Joshi M, Joshi P, Smith JA. Dealing with the Rejected Grant Proposal: Learning from the Mistakes. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:179-187. doi:10.1007/978-981-19-7018-4_16 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_16
- Rahi M, Sharma S, Yadav B. Funders' Perspective: What the Funding Body Expects from Researchers? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:21-31. doi:10.1007/978-981-19-7018-4_3 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_3
- Dubashi B, Ramadass B. Funding Organizations for Science and Health Care. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:33-52. doi:10.1007/978-981-19-7018-4_4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_4
- Parija SC, Kate V (eds). Grant writing for medical and healthcare professionals. Springer, Singapore. 2023. doi:10.1007/978-981-19-7018-4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4
- Weidmann AE, Cadogan CA, Fialova D, et al. How to write a successful grant application: guidance provided by the European Society of Clinical Pharmacy. International Journal of Clinical Pharmacy. 2023;45(3):781-786. doi:10.1007/s11096-023-01543-7 read 9 October 2026. doi.org/10.1007/s11096-023-01543-7
- Obtaining Letters of Support. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:53-59. doi:10.1007/978-981-19-7018-4_5 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_5
- Singaravelu SLD. Proving the Competency of the Researcher and the Adequacy of the Infrastructure to Carry Out the Research. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:93-101. doi:10.1007/978-981-19-7018-4_8 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_8
- Nachiappa Ganesh R. Tips for Improvising the Chance of Getting the Grant. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:167-177. doi:10.1007/978-981-19-7018-4_15 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_15
- Parija SC, Shrivastava SR. What Is Your Aim (Ambition-Interest-Mission), and What You Want to Do? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:3-12. doi:10.1007/978-981-19-7018-4_1 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_1
- What Is a Grant? How to Prepare a Grant Proposal Application. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:13-20. doi:10.1007/978-981-19-7018-4_2 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_2
- Kate V, Gupta D, Balakrishnan G. Writing a Grant Proposal for a Single Centre Study: Step-by-Step Approach. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:63-76. doi:10.1007/978-981-19-7018-4_6 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_6
- Ganguly NK, Saha GK. Writing an Impressive Cover Page (Covering Letter) and Abstract for Grant Proposal Application. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:117-131. doi:10.1007/978-981-19-7018-4_10 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_10
- Monavarian M. Basics of scientific and technical writing: Grant proposals. MRS Bulletin. 2021;46(5):455-457. doi:10.1557/s43577-021-00105-4 read 9 October 2026. doi.org/10.1557/s43577-021-00105-4
- Dhir SK, Gupta P. Formulation of Research Question and Composing Study Outcomes and Objectives. Indian Pediatrics. 2021;58:584-588. read 9 October 2026. indianpediatrics.net
- Kan P, Mokin M, Mack WJ, et al. Strategies for writing a successful National Institutes of Health grant proposal for the early-career neurointerventionalist. Journal of NeuroInterventional Surgery. 2020. doi:10.1136/neurintsurg-2020-016964 read 9 October 2026. doi.org/10.1136/neurintsurg-2020-016964
- Taylor RB. How to Write a Research Protocol. Medical Writing (Springer, Cham). 2018:239-260. doi:10.1007/978-3-319-70126-4_9 read 9 October 2026. doi.org/10.1007/978-3-319-70126-4_9
- Shepherd J, Frampton GK, Pickett K, et al. Peer review of health research funding proposals: A systematic map and systematic review of innovations for effectiveness and efficiency. PLoS ONE. 2018;13(5):e0196914. doi:10.1371/journal.pone.0196914 read 9 October 2026. doi.org/10.1371/journal.pone.0196914
- Boyack KW, Smith C, Klavans R. Toward predicting research proposal success. Scientometrics. 2018;114(2):449-461. doi:10.1007/s11192-017-2609-2 read 9 October 2026. doi.org/10.1007/s11192-017-2609-2
- Dey SK, Gerhardt K. How to Write a Competitive R01 Grant. Springer, Cham. 2016. doi:10.1007/978-3-319-41360-0 read 9 October 2026. doi.org/10.1007/978-3-319-41360-0
- Introduction: Fear of Uncertainty - Enter at Your Own Risk. How to Write a Competitive R01 Grant (Springer, Cham). 2016:1-18. doi:10.1007/978-3-319-41360-0_1 read 9 October 2026. doi.org/10.1007/978-3-319-41360-0_1
- Barnett AG, Herbert DL, Campbell M, et al. Streamlined research funding using short proposals and accelerated peer review: an observational study. BMC Health Services Research. 2015;15(1):55. doi:10.1186/s12913-015-0721-7 read 9 October 2026. doi.org/10.1186/s12913-015-0721-7
- Agency for Healthcare Research and Quality. Common Problems Identified During Peer Review. Agency for Healthcare Research and Quality (AHRQ). 2014. read 9 October 2026. ahrq.gov
- Herbert DL, Barnett AG, Clarke P, Graves N. On the time spent preparing grant proposals: an observational study of Australian researchers. BMJ Open. 2013;3(5):e002800. doi:10.1136/bmjopen-2013-002800 read 9 October 2026. doi.org/10.1136/bmjopen-2013-002800
- Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200-207. doi:10.7326/0003-4819-158-3-201302050-00583 read 9 October 2026. doi.org/10.7326/0003-4819-158-3-201302050-00583
- Abdoul H, Perrey C, Amiel P, et al. Peer Review of Grant Applications: Criteria Used and Qualitative Study of Reviewer Practices. PLoS ONE. 2012;7(9):e46054. doi:10.1371/journal.pone.0046054 read 9 October 2026. doi.org/10.1371/journal.pone.0046054
- National Institute of Allergy and Infectious Diseases (NIAID). Strategy for NIH Funding: Ten Steps to a Winning R01 Application. National Institutes of Health (NIAID). 2012. read 9 October 2026. ipr.osu.edu
- Proctor EK, Powell BJ, Baumann AA, et al. Writing implementation research grant proposals: ten key ingredients. Implementation Science. 2012;7(1):96. doi:10.1186/1748-5908-7-96 read 9 October 2026. doi.org/10.1186/1748-5908-7-96
- Hollins Martin CJ, Fleming V. A 15-step model for writing a research proposal. British Journal of Midwifery. 2011;18:791-798. read 9 October 2026. napier-repository.worktribe.com
- Eve J. Writing a research proposal: planning and communicating your research ideas effectively. Library and Information Research. 2009;32(102):18-28. doi:10.29173/lirg92 read 9 October 2026. doi.org/10.29173/lirg92
- SUNY Geneseo Sponsored Research (adapted from Locke, Spirduso and Silverman, Proposals That Work, 2nd ed., Sage, 1987). Common Reasons Grant Proposals Are Rejected. SUNY Geneseo Office of Sponsored Research. read 9 October 2026. geneseo.edu
- National Institute of Mental Health. Grant Writing Assistance. National Institutes of Health (NIMH). read 9 October 2026. nimh.nih.gov
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans. Pubrica. https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/
Pubrica Academy. “Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans.” Pubrica, 9 Oct. 2026, pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/.
Pubrica Academy (2026) Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans. Pubrica. Available at: https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/ (Accessed: 15 October 2026).
Pubrica Academy. “Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans.” Pubrica. October 9, 2026. https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/
Pubrica Academy, ‘Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/> accessed 15 October 2026.
Pubrica Academy. Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/
Pubrica Academy, “Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/
@misc{structure_for_writing_a_scientific_res_2026,
author = {{Pubrica Academy}},
title = {Structuring a Biotechnology Research Proposal: Page Budgets, Specific Aims and Work Plans},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/research/structure-for-writing-a-scientific-research-proposal-in-biotechnology/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Specific Aims skeleton and page-budget worksheet
Two templates are provided. The first is a page-budget worksheet to be completed before drafting; the second is a Specific Aims skeleton with the essential blanks marked. The worksheet should be completed first, because it determines the permitted length of the aims page.
PART 1. PAGE BUDGET WORKSHEET (complete before drafting)
Funder and scheme: ______________________________
Call document date: ______________ Deadline: ______________
HARD LIMITS copied from the call document:
Total technical pages, excluding references ......... ______
Aims / introduction pages .......................... ______
Research plan / strategy pages ..................... ______
Other mandated sections (list) ..................... ______
Project term allowed, in years ..................... ______
MY ALLOCATION (must sum to the total above):
Aims or introduction ............................... ______ pp
Significance and gap ............................... ______ pp
Feasibility and preliminary data ................... ______ pp
Research plan, Thrust 1 ............................ ______ pp
Research plan, Thrust 2 ............................ ______ pp
Research plan, Thrust 3 (if any) ................... ______ pp
Risks, alternatives, rigour ........................ ______ pp
Timeline and management ............................ ______ pp
TOTAL .............................................. ______ pp
[ ] Total equals the hard limit
[ ] Feasibility has at least as many pages as one thrust
[ ] Human participants or samples involved? yes / no
If yes, pages reserved for governance paragraph: ______
PART 2. SPECIFIC AIMS SKELETON (one page, in this order)
PARAGRAPH 1 - THE PROBLEM (3 to 4 sentences)
The field currently relies on / is limited by:
____________________________________________
This matters because (who is affected, and how):
____________________________________________
What is NOT known:
____________________________________________
PARAGRAPH 2 - THE CLAIM (3 to 4 sentences)
Our central hypothesis or objective is:
____________________________________________
This is based on our own prior finding that:
____________________________________________ [cite your own data]
We are positioned to do this because we have:
____________________________________________ [platform, access, cohort]
AIMS (2 to 4; 3 is the usual choice)
AIM 1. Determine whether ____________________________________
Comparator or baseline: ______________________
Approach, in one sentence: ______________________
Measured endpoint and the assay for it: ______________________
Outcome if the answer is yes: ______________________
Outcome if the answer is no, and what it redirects: ______________
Independent of other aims? yes / no (if no, state the contingency)
AIM 2. Determine whether ____________________________________
Comparator or baseline: ______________________
Approach, in one sentence: ______________________
Measured endpoint and the assay for it: ______________________
Outcome if the answer is yes: ______________________
Outcome if the answer is no, and what it redirects: ______________
Independent of other aims? yes / no
AIM 3. Determine whether ____________________________________
(same fields)
CLOSING PARAGRAPH (2 to 3 sentences)
At the end of this award the field will be able to:
____________________________________________
The next step this work makes possible:
____________________________________________
PART 3. PLAN SKELETON (thrusts and tasks)
THRUST 1 (maps to Aim ____): ______________________________
Task 1.1 ______________________ owner ______ months ____ to ____
deliverable: ______________ if it fails: ______________
Task 1.2 ______________________ owner ______ months ____ to ____
deliverable: ______________ if it fails: ______________
Task 1.3 ______________________ owner ______ months ____ to ____
deliverable: ______________ if it fails: ______________
THRUST 2 (maps to Aim ____): ______________________________
Task 2.1 ... (same fields)
THRUST 3 (maps to Aim ____): ______________________________
Task 3.1 ... (same fields)
PART 4. RECONCILIATION PASS (do this as a separate, final check)
[ ] Every aim number in the aims page appears in the plan
[ ] Every task identifier appears in the timeline
[ ] Every task's personnel and consumables appear in the budget justification
[ ] The same words are used for the same work in all four places
[ ] One primary objective stated; secondary objectives number 5 or fewer
[ ] Each secondary objective is answerable without the primary succeeding
(if not, move it to Risks and Alternatives)
[ ] Project term in the timeline matches the term the scheme allows
[ ] No capability is asserted without evidence or a stated plan to build it Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica addresses proposal structure before the scientific content is drafted: the page budget is laid out against the funder’s call document, each Specific Aim is tested for independence and for a scorable outcome, and the aims, plan, timeline and budget justification are reconciled with one another. Where a biotechnology proposal has a translational or human component, the protocol and governance items that the technical volume must acknowledge are identified. Pubrica also indicates where its advice reflects funder convention rather than evidence, since in this subject area a considerable proportion of it does.